CAPEK JOHN M
Known title: EXECUTIVE VICE PRESIDENTCIK: 0001328034
Associated companies
Transaction History
| ABT | ▼ Sell | Tax Withholding | 6,247 | $623K | 2/28/2023 | View on chart |
| ABT | ▲ Buy | Grant | 15,855 | $0 | 2/17/2023 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 7,086 | $867K | 2/28/2022 | View on chart |
| ABT | ▲ Buy | Grant | 15,523 | $0 | 2/18/2022 | View on chart |
| ABT | ▲ Buy | Option Exercise | 149,600 | $5.2M | 12/13/2021 | View on chart |
| ABT | ▼ Sell | Open Market | 149,600 | $20.2M | 12/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Abbott Labs launches Ensure Max Protein as earnings preview approaches
Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.
Abbott Labs launches Ensure Max Protein as earnings preview approaches. Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.